title: Optimising parameters for peripheral blood leukapheresis after r-metHuG-CSF (filgrastim) and r-metHuSCF (ancestim) in patients with multiple myeloma: a temporal analysis of CD34(+) absolute counts and subsets.
abstract: Patients (n = 69) with multiple myeloma undergoing peripheral blood stem cell collection (PBSC) were treated with cyclophosphamide and a combination of recombinant methionyl human granulocyte colony-stimulating factor (r-metHuG-CSF, filgrastim) and recombinant methionyl human stem cell factor (r-metHuSCF, ancestim). The objectives of this study were to determine: (1) The proportion of patients reaching a target yield of >or=5 x 10(6) CD34(+) cells/kg in one or two successive large-volume (20 liter) leukapheresis procedures; (2) the optimal collection time for leukapheresis; (3) mobilization kinetics of CD34(+) subsets in response to G-CSF/SCF. All patients were mobilized with cyclophosphamide (2.5 g/m(2)) on day 0 followed by filgrastim (10 microg/kg ) plus ancestim (20 microg/kg) commencing day 1 and continuing to day 11 or 12. Of the 65 evaluable patients, 57 were considered not heavily pretreated and 96.5% obtained a target of >or=5 x 10(6)/kg in one collection. The median CD34(+) cells/kg was 39.5 x 10(6) (range: 5.2-221.2 x 10(6)). Subset analysis demonstrated the number of CD38(-), CD33(-), and CD133(+) peaked at day 11; and CD34(+), CD90(+) cells peaked at day 10. The optimum day for leukapheresis was determined to be day 11. The median absolute peripheral blood CD34(+) cell numbers on day 11 was 665 x 10(6)/l (range: 76-1481 x 10(6)/l). Eight of the 10 heavily pretreated patients were evaluable: three achieved the target dose in one leukapheresis (37.5%) and three (37.5%) achieved the target dose with two leukaphereses. Use of this mobilization strategy allowed the collection of high numbers of CD34(+) cells and early progenitors and the ability to predictably schedule leukapheresis.
authors.affiliation: London Health Sciences Centre, London, ON, Canada.
authors.forename: I H
authors.initials: IH
authors.lastname: Chin-Yee
authors.forename: M
authors.initials: M
authors.lastname: Keeney
authors.forename: A K
authors.initials: AK
authors.lastname: Stewart
authors.forename: A
authors.initials: A
authors.lastname: Belch
authors.forename: I
authors.initials: I
authors.lastname: Bence-Buckler
authors.forename: S
authors.initials: S
authors.lastname: Couban
authors.forename: K
authors.initials: K
authors.lastname: Howson-Jan
authors.forename: M
authors.initials: M
authors.lastname: Rubinger
authors.forename: D
authors.initials: D
authors.lastname: Stewart
authors.forename: R
authors.initials: R
authors.lastname: Sutherland
authors.forename: V
authors.initials: V
authors.lastname: Paragamian
authors.forename: M
authors.initials: M
authors.lastname: Bhatia
authors.forename: R
authors.initials: R
authors.lastname: Foley
mesh_terms: D000328:Adult; D000368:Aged; D018952:Antigens, CD34 / Q000032:analysis; D001772:Blood Cell Count; D003520:Cyclophosphamide; D005260:Female; D000069585:Filgrastim; D005434:Flow Cytometry; D016179:Granulocyte Colony-Stimulating Factor; D019650:Hematopoietic Stem Cell Mobilization; D006412:Hematopoietic Stem Cells / Q000187:drug effects; D006801:Humans; D016130:Immunophenotyping; D007937:Leukapheresis / Q000379:methods*; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000097:blood* / Q000628:therapy; D011994:Recombinant Proteins; D019089:Stem Cell Factor / Q000031:analogs & derivatives
chemical_list: D018952:Antigens, CD34; D011994:Recombinant Proteins; D019089:Stem Cell Factor; D016179:Granulocyte Colony-Stimulating Factor; D003520:Cyclophosphamide; D000069585:Filgrastim; C105861:ancestim